Dana-Farber Cancer Institute: PARP Inhibition Shows Long-Term Survival Benefits for Patients With High-Risk, BRCA-Positive Breast Cancer
December 13, 2024
December 13, 2024
BOSTON, Massachusetts, Dec. 13 (TNSres) -- The Dana-Farber Cancer Institute issued the following news release:
Patients with high-risk, BRCA-positive breast cancer who received olaparib after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS).
"The Oly . . .
Patients with high-risk, BRCA-positive breast cancer who received olaparib after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS).
"The Oly . . .